基于加拿大健康测量调查数据的加拿大麻疹人群免疫力研究——加拿大免疫研究网络(CIRN)研究
该研究检测了加拿大健康测量调查(CHMS)第2周期(2009-2011)和第3周期(2011-2013)队列生物库中的11176份血清,先用BioPlex 2220 MMRV IgG法检测,再对全部阴性及可疑样本用更敏感的蚀斑减少中和试验(PRNT)复测,按年龄、性别、地区和出生地加权计算麻疹抗体阳性比例。结果显示90.0%(95%CI:88.2,91.9)的样本为阳性,4.5%(95%CI:3.4,5.5)为可疑,5.5%(95%CI:4.3,6.7)为阴性;12-19岁年龄组阳性比例最低,为78.7%(95%CI:74.2,83.2),60-79岁组最高,为99.6%(95%CI:99.3,99.9)。作者结论认为加拿大麻疹免疫力低于维持消除所需的95%免疫阈值。
要点
- 11176份血清中90.0%为麻疹抗体阳性,4.5%为可疑,5.5%为阴性。
- 12-19岁组阳性比例最低(78.7%),60-79岁组最高(99.6%)。
- 加拿大麻疹免疫力低于维持消除所需的95%免疫阈值。
核心结论
- 加拿大麻疹免疫力低于维持麻疹消除所需的95%免疫阈值,凸显维持高疫苗覆盖率以预防未来麻疹暴发和维持加拿大消除状态的重要性。
研究设计与样本
- 研究检测了来自加拿大统计局加拿大健康测量调查(CHMS)第2周期(2009-2011)和第3周期(2011-2013)队列生物库的11176份血清,先用BioPlex 2220 MMRV IgG法检测,再对全部阴性和可疑样本用更敏感的蚀斑减少中和试验(PRNT)复测,并按年龄、性别、地区和是否在加拿大出生加权计算阳性、可疑和阴性样本比例。
主要发现
- 90.0%(95%CI:88.2,91.9)的样本为阳性,4.5%(95%CI:3.4,5.5)为可疑,5.5%(95%CI:4.3,6.7)为阴性。
- 12-19岁年龄组阳性比例最低,为78.7%(95%CI:74.2,83.2);60-79岁组阳性比例最高,为99.6%(95%CI:99.3,99.9)。
- 在6-39岁的广泛儿童和成人年龄组中,血清阳性率始终低于90%。
- 女性阳性比例略高于男性:女性91.9%(95%CI:90.1,93.6),男性88.3%(95%CI:85.8,90.7)。
- 考虑年龄与出生地的交互作用,在加拿大出生且年龄≤19岁者较境外出生者不易感(OR=0.6,95%CI:0.4,0.95),而年龄≥20岁者更易感(OR=1.7,95%CI:1.1,2.8)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We aimed to determine population immunity to measles in Canada, and to assess the risk of future outbreaks. We tested 11,176 sera from Cycles 2 (2009-2011) and 3 (2011-2013) cohorts from the biobank of Statistics Canada's Canadian Health Measures Survey (CHMS) using the BioPlex 2220 MMRV IgG assay. We then tested all BioPlex negative and equivocal samples using a more sensitive Plaque Reduction Neutralization Test (PRNT). We determined the weighted proportion of positive, equivocal, and negative samples by age, sex, region and whether individuals were born in Canada. We found that 90.0% (95% confidence interval (CI): 88.2, 91.9) of samples were positive, 4.5% (95% CI: 3.4, 5.5) were equivocal and 5.5% (95% CI: 4.3, 6.7) were negative. Individuals in the 12-19 year age band had the lowest proportion positive at 78.7% (95% CI: 74.2, 83.2) and the highest proportion of positive samples was found in those 60-79 years (99.6%, 95% CI: 99.3, 99.9). Seropositivity was consistently <90% across a broad range of pediatric and adult age bands (6-39 years). We found that a slightly higher proportion of females were positive (91.9%, 95% CI: 90.1, 93.6) compared to males (88.3%, 95% CI: 85.8, 90.7). When taking into account interaction between age and born in Canada status, we found individuals born in Canada aged 19 and under were less susceptible (OR = 0.6 (95% CI: 0.4, 0.95)) compared to those born outside Canada whereas, those aged 20 and over were more susceptible (OR = 1.7 (95% CI: 1.1, 2.8)). Our findings indicate that measles immunity in Canada is below the 95% immunity threshold required to sustain measles elimination, underscoring the importance of maintaining high vaccine coverage to prevent future measles outbreaks and sustain Canada's elimination status.
引用
- Osman S, Crowcroft N, McLachlan E, et al. Population immunity to measles in Canada using Canadian Health Measures survey data - A Canadian Immunization Research Network (CIRN) study. Vaccine. 2022. PMID: 35491342. doi:10.1016/j.vaccine.2022.04.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。